ASCO 2009 - A Randomized, Double-Blind Phase III Study of Pazopanib in Treatment-Naive and Cytokine-Pretreated Patients with Advanced Renal Cell Carcinoma - Session Presentation
ORLANDO, FL, USA (UroToday.com) - Study results indicate a favorable risk/benefit profile in treatment of patients with treatment-naive and cytokine-pretreated advanced RCC.
|
UroToday, 1802 Fifth Street, Berkeley CA 94710 510.540.0930 (fax), info@urotoday.com ISSN 1939-4810
Privacy Policy | © 2009 UroToday ® All Rights Reserved |





